MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP

Cancer Cell

Volumn 3, Issue 3, 2003, Pages 259-271

  Deguchi, Kenji ^a,g   Ayton, Paul M ^b   Carapeti, Melina ^a   Kutok, Jeffery L ^c   Snyder, Cynthia S ^d   Williams, Ifor R ^e   Cross, Nicholas C P ^f   Glass, Christopher K ^d   Cleary, Michael L ^b   Gilliland, D Gary ^a,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; HYBRID PROTEIN; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; TRANSCRIPTION FACTOR TIF2; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ACYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MYST3 PROTEIN, HUMAN; NCOA2 PROTEIN, HUMAN; NCOA2 PROTEIN, MOUSE; NUCLEAR PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 2; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; IN VITRO STUDY; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CHROMOSOME 8; CHROMOSOME INVERSION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METABOLISM; POINT MUTATION; PROTEIN TERTIARY STRUCTURE; VIRUS CELL TRANSFORMATION;

ANIMALIA; MURINAE;

ACETYLTRANSFERASES; ANIMALS; BONE MARROW TRANSPLANTATION; CELL LINE; CELL TRANSFORMATION, VIRAL; CHROMOSOMES, HUMAN, PAIR 8; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE ACETYLTRANSFERASES; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MODELS, MOLECULAR; NUCLEAR PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 2; NUCLEOSOMES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 0041785491     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00051-5     Document Type: Article

References (48)

1. Akhtar A., Becker P.B. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol. Cell. 5:2000;367-375.
2. Akhtar A., Becker P.B. The histone H4 acetyltransferase MOF uses a C2HC zinc finger for substrate recognition. EMBO Rep. 2:2001;113-118.
3. Ayton P.M., Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 20:2001;5695-5707.
4. Billio A., Steer E.J., Pianezze G., Svaldi M., Casin M., Amato B., Coser P., Cross N.C. A further case of acute myeloid leukaemia with inv(8)(p11q13) and MOZ- TIF2 fusion. Haematologica. 87:2002;ECR15.
5. Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G., Chaganti R.S., Civin C.I., Disteche C., Dube I., Frischauf A.M., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 14:1996;33-41.
6. Boyes J., Byfield P., Nakatani Y., Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 396:1998;594-598.
7. Carapeti M., Aguiar R.C., Goldman J.M., Cross N.C. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 91:1998;3127-3133.
8. Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pebusque M.J. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer. 28:2000;138-144.
9. Chakraborty S., Senyuk V., Nucifora G. Genetic lesions and perturbation of chromatin architecture. a road to cell transormation J. Cell. Biochem. 8:2001;310-325.
10. Champagne N., Pelletier N., Yang X.J. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. Oncogene. 20:2001;404-409.
11. Demarest S.J., Martinez-Yamout M., Chung J., Chen H., Xu W., Dyson H.J., Evans R.M., Wright P.E. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature. 415:2002;549-553.
12. Ding X.F., Anderson C.M., Ma H., Hong H., Uht R.M., Kushner P.J., Stallcup M.R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1). multiple motifs with different binding specificities Mol. Endocrinol. 12:1998;302-313.
13. DiMartino J.F., Miller T., Ayton P.M., Landewe T., Hess J.L., Cleary M.L., Shilatifard A. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 96:2000;3887-3893.
14. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:1997;222-232.
15. Grant P.A., Berger S.L. Histone acetyltransferase complexes. Semin. Cell Dev. Biol. 10:1999;169-177.
16. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
17. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 387:1997;733-736.
18. Horwitz K.B., Jackson T.A., Bain D.L., Richer J.K., Takimoto G.S., Tung L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10:1996;1167-1177.
19. Hung H.L., Lau J., Kim A.Y., Weiss M.J., Blobel G.A. CREB-binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol. Cell. Biol. 19:1999;3496-3505.
20. Ida K., Kitabayashi I., Taki T., Taniwaki M., Noro K., Yamamoto M., Ohki M., Hayashi Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood. 90:1997;4699-4704.
21. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:2002;310-318.
22. Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 20:2001;7184-7196. a.
23. Kitabayashi I., Aikawa Y., Yokoyama A., Hosoda F., Nagai M., Kakazu N., Abe T., Ohki M. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 15:2001;89-94. b.
24. Klein-Hitpass L., Tsai S.Y., Weigel N.L., Allan G.F., Riley D., Rodriguez R., Schrader W.T., Tsai M.J., O'Malley B.W. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. Cell. 60:1990;247-257.
25. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., Mullen T.M., Glass C.K., Rosenfeld M.G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 279:1998;703-707.
26. Kung A.L., Rebel V.I., Bronson R.T., Ch'ng L.E., Sieff C.A., Livingston D.M., Yao T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14:2000;272-277.
27. Lavau C., Szilvassy S.J., Slany R., Cleary M.L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 16:1997;4226-4237.
28. Lavau C., Du C., Thirman M., Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 19:2000;4655-4664. a.
29. Lavau C., Luo R.T., Du C., Thirman M.J. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc. Natl. Acad. Sci. USA. 97:2000;10984-10989. b.
30. Leo C., Chen J.D. The SRC family of nuclear receptor coactivators. Gene. 245:2000;1-11.
31. Liang J., Prouty L., Williams B.J., Dayton M.A., Blanchard K.L. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood. 92:1998;2118-2122.
32. Liu Q., Schwaller J., Kutok J., Cain D., Aster J.C., Williams I.R., Gilliland D.G. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19:2000;1827-1838.
33. Mizzen C.A., Brownell J.E., Cook R.G., Allis C.D. Histone acetyltransferases. preparation of substrates and assay procedures Methods Enzymol. 304:1999;675-696.
34. Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U., Billstrom R., Strombeck B., Mitelman F., Johansson B. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum. Mol. Genet. 10:2001;395-404.
35. Pear W.S., Nolan G.P., Scott M.L., Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:1993;8392-8396.
36. Pelletier N., Champagne N., Stifani S., Yang X.J. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene. 21:2002;2729-2740.
37. Petrij F., Giles R.H., Dauwerse H.G., Saris J.J., Hennekam R.C., Masuno M., Tommerup N., van Ommen G.J., Goodman R.H., Peters D.J., et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 376:1995;348-351.
38. Satake N., Ishida Y., Otoh Y., Hinohara S., Kobayashi H., Sakashita A., Maseki N., Kaneko Y. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosomes Cancer. 20:1997;60-63.
39. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R. Jr. , et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17:1998;5321-5333.
40. Slany R.K., Lavau C., Cleary M.L. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell. Biol. 18:1998;122-129.
41. Sobulo O.M., Borrow J., Tomek R., Reshmi S., Harden A., Schlegelberger B., Housman D., Doggett N.A., Rowley J.D., Zeleznik-Le N.J. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. USA. 94:1997;8732-8737.
42. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64:2000;435-459.
43. Takechi S., Nakayama T. Sas3 is a histone acetyltransferase and requires a zinc finger motif. Biochem. Biophys. Res. Commun. 266:1999;405-410.
44. Taki T., Sako M., Tsuchida M., Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 89:1997;3945-3950.
45. Tomasson M.H., Sternberg D.W., Williams I.R., Carroll M., Cain D., Aster J.C., Ilaria R.L. Jr., Van Etten R.A., Gilliland D.G. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J. Clin. Invest. 105:2000;423-432.
46. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., Rosenfeld M.G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:1997;677-684.
47. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519.
48. Zhang W., Bieker J.J. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl. Acad. Sci. USA. 95:1998;9855-9860.